40 related articles for article (PubMed ID: 25652546)
1. Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy.
Lin J; Wang W; Xu Y; Di Bisceglie AM; Fan X
J Med Virol; 2015 May; 87(5):821-8. PubMed ID: 25652546
[TBL] [Abstract][Full Text] [Related]
2. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.
Boo I; Fischer AE; Johnson D; Chin R; Giourouki M; Bharadwaj M; Bowden S; Torresi J; Drummer H
J Clin Virol; 2007 Aug; 39(4):288-94. PubMed ID: 17569577
[TBL] [Abstract][Full Text] [Related]
4. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
Chu CM; Sheen IS; Liaw YF
Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
[TBL] [Abstract][Full Text] [Related]
5. Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study.
Kee KM; Wang JH; Hung CH; Chen CH; Lee CM; Chang KC; Tseng PL; Yen YH; Lin CY; Lu SN
J Gastroenterol Hepatol; 2012 Jun; 27(6):1106-11. PubMed ID: 22004331
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.
Pedersen J; Jensen TB; Carlsen TH; Schønning K; Christensen PB; Laursen AL; Krarup H; Bukh J; Weis N
PLoS One; 2013; 8(5):e62674. PubMed ID: 23667506
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
8. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
9. Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR.
Vigón L; Vázquez-Morón S; Berenguer J; González-García J; Jiménez-Sousa MÁ; Guardiola JM; Crespo M; de Los Santos I; Von Wichmann MA; Carrero A; Yélamos MB; Gómez J; Resino S; Martínez I;
Sci Rep; 2019 Aug; 9(1):12163. PubMed ID: 31434968
[TBL] [Abstract][Full Text] [Related]
10. Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers.
Depraetere S; Van Kerschaever E; Van Vlierberghe H; Elewaut A; Brouwer JT; Niesters HG; Schalm SW; Maertens G; Leroux-Roels G
J Med Virol; 2000 Feb; 60(2):126-32. PubMed ID: 10596010
[TBL] [Abstract][Full Text] [Related]
11. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
12. Low cross-neutralization of hepatitis C correlates with liver disease in immunocompromized patients.
Maurin G; Halgand B; Bruscella P; Fresquet J; Duclos-Vallée JC; Roque-Afonso AM; Cosset FL; Samuel D; Lavillette D; Féray C
AIDS; 2015 Jun; 29(9):1025-33. PubMed ID: 26125137
[TBL] [Abstract][Full Text] [Related]
13. Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization.
Vercauteren K; Mesalam AA; Leroux-Roels G; Meuleman P
World J Gastroenterol; 2014 Nov; 20(43):15975-91. PubMed ID: 25473151
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection.
Hou J; van Oord G; Groothuismink ZM; Claassen MA; Kreefft K; Zaaraoui-Boutahar F; van IJcken WF; Osterhaus AD; Janssen HL; Andeweg AC; de Knegt RJ; Boonstra A
J Virol; 2014 Nov; 88(21):12254-64. PubMed ID: 25100847
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection.
Pedersen J; Lundbo LF; Krarup H; Bukh J; Weis N
J Med Virol; 2016 Oct; 88(10):1791-803. PubMed ID: 27027386
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion.
Raghuraman S; Park H; Osburn WO; Winkelstein E; Edlin BR; Rehermann B
J Infect Dis; 2012 Mar; 205(5):763-71. PubMed ID: 22293431
[TBL] [Abstract][Full Text] [Related]
17. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses.
Veerapu NS; Raghuraman S; Liang TJ; Heller T; Rehermann B
Gastroenterology; 2011 Feb; 140(2):676-685.e1. PubMed ID: 21040725
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Anti-HCV Antibodies in IL-10-Treated Patients.
Eksioglu EA; Bess J; Jones G; Dettloff J; Dangmeon P; Dong HJ; Zhu H; Firpi R; Xu Y; Nelson DR; Liu C
Viral Immunol; 2010 Aug; 23(4):359-68. PubMed ID: 20712480
[TBL] [Abstract][Full Text] [Related]
19. Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.
Tawar RG; Heydmann L; Bach C; Schüttrumpf J; Chavan S; King BJ; McClure CP; Ball JK; Pessaux P; Habersetzer F; Bartenschlager R; Zeisel MB; Baumert TF
Hepatology; 2016 Nov; 64(5):1495-1506. PubMed ID: 27531416
[TBL] [Abstract][Full Text] [Related]
20. Specific immunoglobulin against hepatitis C virus. Why not?
Piazza M
Infez Med; 2012 Sep; 20(3):214-6. PubMed ID: 22992564
[No Abstract] [Full Text] [Related]
[Next] [New Search]
